Discover recent advancements in multiple sclerosis diagnosis from leading neurologist and researcher Dr. Franz Felix Konen.
Discover how risk stratification in smoldering multiple myeloma (SMM) is evolving to include dynamic biomarkers that reflect disease progression over time.
Learn about emerging therapies in AL amyloidosis, including combining targeted amyloid removal with existing treatments.
Learn about new recommendations for chronic kidney disease (CKD) detection, staging, risk assessment and treatment.
Discover the uses of serum calprotectin in adult and pediatric patients suffering from autoinflammatory diseases.
Understand the clinical and laboratory aspects that affect serum FLC testing in diagnosis and monitoring of monoclonal gammopathies.
Understand more about the role of biomarkers in inflammatory disease in the central nervous system (kappaFLC & sNFL).
Serum amyloid A as an early predictor of severity in COVID-19
Learn about Serum amyloid A (SAA) and its utility in COVID-19 disease management.
Diagnosis of kidney dysfunction
Learn more about kidney dysfunction diagnosis, including recent recommendations on the calculation of estimated glomerular filtration rate (eGFR).
FLC testing in multiple myeloma and kidney disease: An American Perspective
Learn about free light chain (FLC) testing in multiple myeloma and the influence of kidney function on FLC test results.
FLC testing in multiple myeloma and kidney disease: A Chinese Perspective
Learn about FLC testing in multiple myeloma and the influence of kidney function on FLC test results.
FLC testing in the diagnosis and monitoring of AL amyloidosis
Learn about free light chain (FLC) testing in the detection and monitoring of amyloidosis.
The importance of FLC testing in MGUS patients
Understand the key role of free light chain (FLC) testing in the detection and monitoring of MGUS.
kFLC in CSF as a diagnostic marker for multiple sclerosis
Learn about the role of the kappa free light chain index in cerebrospinal fluid for diagnosis and management of multiple sclerosis.
Learn about the value of serum amyloid A (SAA) and other inflammation markers in the management of hospitalized COVID-19 patients.
